CA3247908A1 - Pharmaceutical composition comprising neurokinin-1 antagonist prodrug compound - Google Patents
Pharmaceutical composition comprising neurokinin-1 antagonist prodrug compoundInfo
- Publication number
- CA3247908A1 CA3247908A1 CA3247908A CA3247908A CA3247908A1 CA 3247908 A1 CA3247908 A1 CA 3247908A1 CA 3247908 A CA3247908 A CA 3247908A CA 3247908 A CA3247908 A CA 3247908A CA 3247908 A1 CA3247908 A1 CA 3247908A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical composition
- composition according
- pharmaceutically acceptable
- acceptable salt
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (23)
- What is claimed is: 1. A pharmaceutical composition, comprising a compound of formula I or a pharmaceutically acceptable salt thereof and a stabilizer, wherein the stabilizer is an amino acid and/or a saccharide, .
- 2. The pharmaceutical composition according to claim 1, wherein the amino acid is an amino acid that contains at least one carboxylic acid group and at least one primary amino group or secondary amino group but does not contain a secondary amide group, preferably alanine, 4-aminobutyric acid, 3-aminopentanoic acid, 5-aminopentanoic acid, 6- aminohexanoic acid, 8-aminooctanoic acid, arginine, aspartic acid, asparagine, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, methyllysine, ornithine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine.
- 3. The pharmaceutical composition according to claim 1, wherein the amino acid is a basic amino acid, preferably arginine, lysine and histidine, and more preferably arginine.
- 4. The pharmaceutical composition according to any one of claims 1-3, wherein the saccharide is selected from one or more of sucrose, glucose, lactose, trehalose and maltose, preferably sucrose and/or glucose, and more preferably glucose.
- 5. The pharmaceutical composition according to claim 1, wherein the stabilizer is14 selected from one or more of arginine, glucose and sucrose, more preferably arginine and/or glucose.
- 6. The pharmaceutical composition according to any one of claims 1-5, wherein the pharmaceutical composition further comprises a solvent, preferably the solvent is selected from water, an organic solvent or a water/organic solvent cosolvent system, and more preferably the solvent is selected from water, ethanol, isopropanol, tert-butanol, water/ethanol, water/isopropanol or water/tert-butanol.
- 7. The pharmaceutical composition according to any one of claims 1-6, wherein the weight ratio of the compound of formula I or the pharmaceutically acceptable salt thereof to the stabilizer is 1 : 0.1-1 : 20, preferably 1 : 1-1 : 10, and more preferably 1 : 1-1 : 7.5.
- 8. The pharmaceutical composition according to claim 6, wherein the compound of formula I or the pharmaceutically acceptable salt thereof has a mass volume percentage of 0.01%-30%, preferably 0.01%-10%, and more preferably 0.1%-5%.
- 9. The pharmaceutical composition according to any one of claims 6-8, wherein the stabilizer has a mass volume percentage of 0.01%-30%, preferably 0.01%-20%, and more preferably 0.1%-10%.
- 10. The pharmaceutical composition according to any one of claims 1-9, wherein the pharmaceutical composition further comprises a buffer, the buffer is preferably a phosphate buffer, a citrate buffer, an acetate buffer, a succinate buffer, a histidine salt buffer or other organic acid salt buffers, and preferably the buffer has a concentration of 5 mM-40 mM, more preferably 10 mM-30 mM.
- 11. The pharmaceutical composition according to any one of claims 1-10, wherein the pharmaceutical composition further comprises a pH regulator.15
- 12. The pharmaceutical composition according to any one of claims 1-11, wherein the pharmaceutical composition further comprises a chelating agent, preferably the chelating agent is ethylenediamine tetraacetic acid or a salt thereof, preferably the chelating agent has a mass volume percentage of 0.001%-5%, more preferably 0.01%-2%, and preferably the weight ratio of the compound of formula I or the pharmaceutically acceptable salt thereof to the chelating agent is 1000 : 1-1 : 1, more preferably 1000 : 1-10 : 1.
- 13. The pharmaceutical composition according to any one of claims 1-12, wherein the pharmaceutical composition has a pH value of 3.0-8.0, preferably 5.0-8.0.
- 14. The pharmaceutical composition according to any one of claims 1-13, wherein the pharmaceutical composition further comprises a 5-HT3 receptor antagonist, preferably the 5- HT3 receptor antagonist is selected from granisetron, ondansetron, ramosetron, tropisetron, palonosetron or dolasetron, more preferably palonosetron, preferably the 5-HT3 receptor antagonist has a mass volume percentage of 0.0001%-1%, more preferably 0.0001%-0.1%, and preferably the weight ratio of the compound of formula I or the pharmaceutically acceptable salt thereof to the 5-HT3 receptor antagonist is 2000 : 1-10 : 1, more preferably 1000 : 1-100 : 1.
- 15. The pharmaceutical composition according to any one of claims 1-14, comprising: a compound of formula I or a pharmaceutically acceptable salt thereof; a stabilizer selected from one or more of arginine, glucose and sucrose; optionally palonosetron or a pharmaceutically acceptable salt thereof; optionally a buffer; optionally a chelating agent.
- 16. The pharmaceutical composition according to any one of claims 1-14, comprising: 0.01%-10% of a compound of formula I or a pharmaceutically acceptable salt thereof; 0.01%-20% of a stabilizer selected from one or more of arginine, glucose and sucrose; optionally 0.0001%-1% of palonosetron or a pharmaceutically acceptable salt thereof;16 optionally a 5 mM-40 mM buffer; optionally 0.01%-2% of a chelating agent; 70%-99% of a solvent selected from water and/or tert-butanol; the percentages are based on mass volume percentages.
- 17. A sterile powder obtained by freeze-drying or spray-drying the pharmaceutical composition according to any one of claims 1-16.
- 18. A sterile powder, which is reconstituted to obtain the pharmaceutical composition according to any one of claims 1-16.
- 19. The sterile powder according to claim 17 or 18, wherein the sterile powder contains less than 5% of prototype drug impurities, preferably less than 4%, more preferably less than 3%, and most preferably less than 2%.
- 20. The sterile powder according to claim 17 or 18, wherein the sterile powder contains less than 5% of prototype drug impurities after being placed at 25 oC and 60% RH for 30 days.
- 21. A reconstituted solution obtained by reconstituting the sterile powder according to any one of claims 17-20.
- 22. A method for preparing the pharmaceutical composition according to any one of claims 1-16, wherein the method comprises the step of mixing a compound of formula I or a pharmaceutically acceptable salt thereof with a stabilizer.
- 23. Use of the pharmaceutical composition according to any one of claims 1-16, the sterile powder according to any one of claims 17-20 or the reconstituted solution according to claim 21 in the preparation of a drug for treating physiological disorders, conditions or diseases in a patient, wherein the physiological disorders, conditions or diseases are preferably respiratory diseases, cough, inflammatory diseases, skin disorders, ophthalmic disorders, depression,17 anxiety, phobia, bipolar disorder, alcohol dependence, neuroactive substance abuse, epilepsy, nociception, psychosis, schizophrenia, Alzheimer's disease, AIDS-related dementia, Towne's disease, stress-related disorders, obsessive/compulsive disorders, bulemia, anorexia nervosa, binge eating, mania, premenstrual syndrome, gastrointestinal dysfunction, atherosclerosis, fibrotic disorder, obesity, type II diabetes, headache, neuropathic pain, post-exercise pain, chronic pain syndrome, bladder disorders, urogenital disorders, vomiting or nausea.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210032508 | 2022-01-12 | ||
| CN202210032508.4 | 2022-01-12 | ||
| PCT/CN2023/071901 WO2023134725A1 (en) | 2022-01-12 | 2023-01-12 | Pharmaceutical composition comprising neurokinin-1 antagonist prodrug compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3247908A1 true CA3247908A1 (en) | 2025-07-10 |
Family
ID=87280118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3247908A Pending CA3247908A1 (en) | 2022-01-12 | 2023-01-12 | Pharmaceutical composition comprising neurokinin-1 antagonist prodrug compound |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20260183319A1 (en) |
| EP (1) | EP4464320B1 (en) |
| JP (1) | JP2025500688A (en) |
| KR (1) | KR20240134358A (en) |
| CN (1) | CN118510509A (en) |
| CA (1) | CA3247908A1 (en) |
| TW (1) | TW202332428A (en) |
| WO (1) | WO2023134725A1 (en) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2464230B1 (en) * | 2009-08-14 | 2016-10-05 | OPKO Health, Inc. | Intravenous formulations of rolapitant |
| WO2019038656A1 (en) * | 2017-08-21 | 2019-02-28 | Leiutis Pharmaceuticals Pvt, Ltd | Novel triple combination formulations for antiemetic therapy |
| US20190358249A1 (en) * | 2018-05-22 | 2019-11-28 | Navinta Iii Inc | Injectable Combination Products Of Fosaprepitant And 5-HT3 Blocker |
| CN111388657B (en) * | 2019-01-03 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | Pharmaceutical composition containing bivalirudin and preparation method thereof |
| KR102940508B1 (en) | 2019-06-28 | 2026-03-16 | 상하이 쉥디 파마슈티컬 컴퍼니 리미티드 | Neurokinin-1 antagonist |
-
2023
- 2023-01-12 CA CA3247908A patent/CA3247908A1/en active Pending
- 2023-01-12 CN CN202380016118.0A patent/CN118510509A/en active Pending
- 2023-01-12 EP EP23740067.6A patent/EP4464320B1/en active Active
- 2023-01-12 JP JP2024541982A patent/JP2025500688A/en active Pending
- 2023-01-12 TW TW112101431A patent/TW202332428A/en unknown
- 2023-01-12 WO PCT/CN2023/071901 patent/WO2023134725A1/en not_active Ceased
- 2023-01-12 KR KR1020247026651A patent/KR20240134358A/en active Pending
- 2023-01-12 US US18/728,162 patent/US20260183319A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4464320C0 (en) | 2026-06-24 |
| CN118510509A (en) | 2024-08-16 |
| WO2023134725A1 (en) | 2023-07-20 |
| US20260183319A1 (en) | 2026-07-02 |
| EP4464320B1 (en) | 2026-06-24 |
| TW202332428A (en) | 2023-08-16 |
| EP4464320A1 (en) | 2024-11-20 |
| EP4464320A4 (en) | 2025-05-14 |
| KR20240134358A (en) | 2024-09-09 |
| JP2025500688A (en) | 2025-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1347760B1 (en) | Nmda receptor agonist pharmaceutical compositions | |
| US12303500B2 (en) | Method for improving stability of low-concentration atropine ophthalmic preparation | |
| US20190105392A1 (en) | Caspofungin Acetate Formulations | |
| CN112805238A (en) | Anhydrous sodium thiosulfate and formulations thereof | |
| US12060439B2 (en) | Polymorph of echinocandin antifungal agent | |
| RU2768482C1 (en) | Pharmaceutical composition of kappa opioid receptor agonist | |
| CN102784382B (en) | Argatroban pharmaceutical composition, and preparation method and application thereof | |
| EP4019033B1 (en) | Injectable solution comprising a spirofused tetrapeptide an a ph-regulator for treating kappa opioid receptor-associated conditions | |
| CN103553996B (en) | Anticholinergic pharmaceutical composition | |
| EP4014965A1 (en) | Aqueous solution | |
| WO2012013116A1 (en) | Pharmaceutical composition of temozolomide comprising amino acid stabilizer and preparation method thereof | |
| EP4464320A1 (en) | Pharmaceutical composition comprising neurokinin-1 antagonist prodrug compound | |
| WO2017185030A1 (en) | Caspofungin formulation with low impurities | |
| JP7855696B2 (en) | Pharmaceutical composition containing 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazoline-4-yl]acetate and potassium ions | |
| EP4601616A1 (en) | Liquid dalbavancin composition | |
| WO2024079223A1 (en) | Liquid dalbavancin composition | |
| JP4875205B2 (en) | Stable preparation of thiadiazole derivatives | |
| EP4609874A1 (en) | Pharmaceutical composition comprising echinocandin analog and preparation method for pharmaceutical composition | |
| CN103845725A (en) | Relatively stable caspofungin composition | |
| CN114306342A (en) | Pharmaceutical composition of imatinib salt for injection and preparation method thereof | |
| HK1215668B (en) | Caspofungin acetate formulations | |
| TW201302755A (en) | Pharmaceutical composition of Temozolomide comprising amino acid stabilizer and preparation method thereof | |
| HK1141238B (en) | Stable formulations of thiadiazole derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240709 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20241217 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241217 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241217 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20241219 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241227 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250130 |
|
| Q12 | Application published |
Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION PUBLISHED (OPEN TO PUBLIC INSPECTION) Effective date: 20250710 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251218 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251218 |